Irmela Jeremias

This paper identifies an acetylation-dependent circuit controlling SEC integrity in AML, showing that disrupting KAT2A/B leads to broad anti-leukemic effects across subtypes.

This study shows that the carbocyclic antimetabolite cAzadC increases TET2 expression and 5hmdC levels, leading to reactivation of anti-tumor responses in AML models.

The paper identifies a TET2-AGO2 regulatory axis that links epigenetic remodeling to myeloid commitment and leukemia progression.

The paper develops patient-derived AML PDX models that replicate primary AML biology and include subgroups lacking existing models, showing reduced leukemia growth after long-term chemotherapy.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

Pyjacker detects enhancer hijacking in AML, identifying MNX1 activation via 7q deletion as a novel oncogenic mechanism.

Prime-seq is a bulk RNA-seq method that is four-fold more cost-efficient than TruSeq while maintaining equivalent library complexity, measurement accuracy, and statistical power.

CLUE is a bioinformatic and wet-lab pipeline that enables the multiplexed generation of custom sgRNA libraries, producing uniform and contamination-free results.